Study wrapper · #1317
Intrathecal semaglutide attenuates burn injury-induced pain in mice through a spinal GLP-1R-linked enkephalin/δ-opioid receptor pathway.
Editor's note
A careful mechanistic study using immunoblotting, immunofluorescence and RNAscope to build a coherent chain from receptor location to behavioural effect, with the female-mouse check that too many rodent pain studies omit. The route matters: intrathecal dosing into the spinal fluid bears no relationship to how semaglutide is used in people, so nothing here transfers to subcutaneous dosing. Read this as basic pharmacology on a spinal GLP-1 to enkephalin pathway, not as evidence about pain in humans.
Plain-language abstract
In a mouse model of second-degree burn injury, researchers found that GLP-1 receptor levels rose in the spinal cord when pain sensitivity peaked, mostly on astrocytes - a type of support cell. Semaglutide delivered directly into the spinal fluid reduced pain-like responses to touch and heat, and blocking the GLP-1 receptor cut that effect. The drug also raised levels of enkephalin, one of the body's own opioid-like molecules, and blocking enkephalin or the delta-opioid receptor removed the pain benefit.